Latest news with #RED
Yahoo
28-05-2025
- Business
- Yahoo
SimpliFi Announces Merger with Staffency, a TotalMed Company, to Enhance Workforce Solutions
LITTLE ROCK, Ark., May 28, 2025 /PRNewswire/ -- SimpliFi, a leading workforce solutions provider, is pleased to announce its merger with Staffency, a TotalMed company, strengthening its ability to deliver innovative, cost-effective, and technology-enabled staffing solutions to healthcare organizations nationwide. This strategic merger unites two industry leaders, combining expertise, technology, and talent to better serve clients and healthcare professionals. Together, the newly merged entity now delivers workforce solutions for over 2,200 care sites across the U.S., expanding service offerings while maintaining a shared commitment to transparency, trust, and accountability. While their mission and culture are highly aligned, each organization brings several unique strengths that enhance their collective capabilities. The merged company offers a broad array of workforce solutions, including contract labor management for physicians, advanced practitioners, nurses, allied health professionals, and non-clinical workers. In addition, the company has expertise in strike staffing, scaling new graduate RN onboarding through its CAP program, and developing internal and external float pools for hospitals. SimpliFi also created and facilitates the RED (Reflect Exchange Define) Labor Summits which bring cross functional groups of healthcare executives together to collaborate on workforce strategy. Health systems require more sophisticated tools to manage their workforce, and this merger brings together two-industry leading technology platforms. Staffency's Vendor Management System (VMS) provides clients with unparalleled visibility into market bill rates, enabling them to make informed, data-driven workforce decisions. SimpliFi's Stogo shift fulfillment platform allows hospitals to optimize their staffing by utilizing their own personnel or local gig workers, helping increase patient care revenue while reducing premium labor costs. "The combination of these two best-in-class organizations creates a workforce solutions provider with the scale, service capabilities, technology, and expertise to tackle the most complex workforce challenges healthcare systems face," said Justin Tomlin, Chief Strategy Officer of Staffency. "Our combined team is anxious to bring these enhanced solutions to both current and future customers." Moving forward, the two companies will operate under the SimpliFi brand, ensuring a seamless transition for clients, employees, and partners. "We knew this merger was right because we share the same core vision: to serve as a true partner to healthcare systems," said James Quick, President of SimpliFi. "By combining our expertise, we will continue to build long-term customer relationships while bringing new and innovative solutions to market." About SimpliFi SimpliFi, founded in 2011, provides workforce management services for some of the nation's leading healthcare systems, academic medical centers, and hospitals in all 50 states. SimpliFi is based in North Little Rock, Arkansas and is part of a family of brands focused exclusively on healthcare staffing and workforce management. About Staffency Staffency is a healthcare workforce solutions provider founded in 2014, specializing in delivering customized staffing strategies to healthcare facilities nationwide. Their Managed Services Provider (MSP) solutions emphasize efficiency, scalability, and accountability, providing streamlined hiring, credential compliance, and real-time analytics. For media inquiries, please contact: Scott KnoxVice President of Marketingsknox@ 604-4893 View original content to download multimedia: SOURCE Travel Nurse Across America Error while retrieving data Sign in to access your portfolio Error while retrieving data
Broadcast Pro
24-05-2025
- Business
- Broadcast Pro
Advanced Media showcases RED Cine-Broadcast module featuring V-RAPTOR XL
The new Cine-Broadcast Module transforms RED's high-end cinema cameras into professional broadcast systems, offering flexibility for a range of live production needs. Advanced Media Trading (AMT) has showcased the Red Cine-Broadcast module, featuring the RED V-RAPTOR XL. This flagship model in the RED lineup of advanced cameras offers the most versatile and powerful cinema camera performance in the market. The RED Cine-Broadcast Module unlocks the flexibility and modularity to turn the most advanced cinema cameras into the most advanced broadcast cameras. It brings cinema quality to broadcast production and highlights groundbreaking imaging technology. RED's Cine-Broadcast module is designed to bring filmic, full-frame imagery to live broadcast workflows. It enables 8K live cinematic streaming and is compliant with SMPTE ST 2110 standards. It provides all functionalities such as colour pipeline for seamless camera shading and iris control with industry standard RCPs. The Red Cine-Broadcast module's most exciting characteristic is its 3x and 4x super slow-motion capabilities, which is suitable for high-end sport, concerts and live event production that require best-in-class image quality. It has been deployed in major sporting events by CBS Sports, NBC Sports Group and La Liga. Capable of doing up to 120FPS at 8K and with a full-frame-sized sensor, the module provides dynamic range, depth of fields and the well-known pleasing image that people are used to only in cinema. Jeff Goodman, Vice President of Product Management at Red Digital Cinema called the Red Cine-Broadcast solution 'a significant advancement in creative flexibility for the industry'. Goodman sad: 'It allows broadcasters to elevate the visual experience by introducing large-format, cinematic storytelling into the world of live content, without compromising on speed, reliability or standards compliance. It works seamlessly within traditional broadcast ecosystems, while adding a myriad of highly advanced IP-based solutions all within the same product.'
Scottish Sun
15-05-2025
- Automotive
- Scottish Sun
‘It's hard for this situation to continue' – Iconic F1 Grand Prix faces being AXED amid ‘difficult' circumstances
It is not the first time the GP has been cut RED FLAG 'It's hard for this situation to continue' – Iconic F1 Grand Prix faces being AXED amid 'difficult' circumstances Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) AN ICONIC F1 grand prix track is at risk of being axed from the race calendar. The Emilia Romagna Grand Prix at Imola could be set to host its last F1 race. Sign up for Scottish Sun newsletter Sign up 4 Emilia Romagna Grand Prix could be cut from the F1 calendar 4 The track was reintroduced back in 2020 4 Stefano Domenicali has said it would be 'difficult' to keep the race Credit: Getty The famous circuit is the host for this weekend's race in the 2025 season. But F1 president Stefano Domenicali has admitted that it could be cut from the calendar. There are currently two races in Italy, the one in Imola as well as the Italian GP at Monza. Domenicali has suggested that with the increased interest in the motorsport, it could prove "difficult" for both to be kept. He told RAI radio: "Italy has always been and will be an important part of Formula 1. "It will be increasingly difficult to have two races in the same country because interest in F1 is growing and it's a situation we will have to deal with in the coming months. "It's hard for this situation with Imola and Monza to continue together on the calendar for long." The Autodromo Internazionale Enzo e Dino Ferrari debuted back in 1981. JOIN SUN VEGAS: GET £50 BONUS However, it has previously been cut as it was left off the calendar from 2006 until it was reintroduced in 2020. This was when the race was rebranded as the Emilia Romagna Grand Prix. Lewis Hamilton fumes 'have a tea break while you're at it' at Ferrari staff and refuses to apologise in Miami GP bust-up 4 No other country in Europe has more than one race but Spain will have next year. This is down to the overlap between the new Madrid track and last year of the Barcelona circuit. The USA has three races with tracks in Miami, Las Vegas and Austin. Speaking in 2024, Domenicali admitted that some tracks in Europe could become rotational in the calendar. He said: "We have some news to share very, very soon with regard to the possibility in the mid-term to have some rotational European Grand Prix and some other new options coming later. "This is something that, of course, we will clarify in the due course. "It is true that we have a large demand for new possible venues that want to come in. "Our choice will always be balanced between the right economic benefits that we can have as a system and also to leverage in the growth of the market. "That we can see potential that will be beneficial for us to grow our business even further." Meanwhile, ahead of this weekend's race Ferrari star Charles Leclerc has missed media duties due to illness.
Yahoo
12-05-2025
- Business
- Yahoo
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
Conference call will be held today, Monday, May 12 at 9:00 am ET CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ('NeurAxis,' or the 'Company') (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025. 1Q25 Financial highlights Revenues increased 39% year over year to $896 thousand in 1Q25 compared to $647 thousand in 1Q24. Revenues increased 18% quarter over quarter to $896 thousand in 1Q25 compared to $761 thousand in 4Q24. Operating loss (excluding a one-time legal settlement) improved by 9% compared to the first quarter of 2024. Cash balance was $2.0 million as of March 31, 2025. Recent Operational Highlights Expanded total covered lives to approximately 51 million compared to 4 million as of December 31 2023. Received a new Current Procedural Terminology (CPT) Category I code for Percutaneous Electrical Nerve Field Stimulation (PENFS) procedures effective January 1, 2026. Received new FDA clearance for the expansion of IB-Stim label: to allow for a larger patient population beyond 11-18 years of age to 8-21 years. to increase devices per patient to 4 devices. Received 510(k) clearance from the FDA for its rectal expulsion device (RED) product. RED's innovative design simplifies anorectal function testing and can be used without interrupting clinical workflow. The Company has just begun the commercialization process and expects the first meaningful revenues in 2Q25. The Company remains committed to clinical research in the pediatric space, with 16 peer-reviewed publications. All studies were carried out in US children's hospitals using NeurAxis' PENFS technology. This level of evidence puts NeurAxis in a great position to continue expanding payor coverage and increasing adoption of the technology. Management Commentary Brian Carrico, Chief Executive Officer of NeurAxis, commented, 'Q1 2025 marked another strong quarter for NeurAxis, with revenue growing 39% year-over-year, extending the momentum that began in Q3 2024. Our progress is becoming increasingly evident in the numbers. In the first quarter alone, 300 patients were treated through full PO or PAP programs—an annualized rate of 1,200 patients. While this marks important growth, it still represents just 0.2% of the 600,000 severely affected children in the U.S. suffering from IBS who are in urgent need of IB-Stim. This robust growth is driven by physicians gaining greater comfort with billing and coding processes, alongside broader awareness of academic society guidelines that recognize PENFS with the highest GRADE of evidence. Today, positive coverage policies now encompass approximately 51 million lives, and several additional payers are actively engaged in policy development. While our revenue trajectory has accelerated in recent quarters, it's important to recognize we are still reaching only a small fraction of our total addressable market, primarily because national policy coverage and the implementation of the Category I CPT code are still forthcoming. We expect the upcoming publication of academic society guidelines to be a significant catalyst for broader insurance coverage, with the goal of securing treatment access for the majority of affected children in the U.S. These coverage expansions, alongside the Category I code taking effect on January 1, 2026, are the two critical milestones that position us for large-scale national growth. In parallel, we have submitted for FDA clearance to expand IB-Stim's indication to include pediatric Functional Dyspepsia, and we are cautiously optimistic for approval in 2025. A successful clearance would effectively double our pediatric addressable market. Our vision is clear: we are methodically executing against our milestones to drive growth, expand access, and deliver on our revenue expectations. We anticipate meaningful acceleration in revenue growth as we move closer to cash flow breakeven, fueled by two catalysts — the continued expansion of positive payer coverage for IB-Stim (PENFS) and the commercialization of RED, alongside the Category I CPT code becoming effective in early 2026." First Quarter 2025 Financial Results Revenues in the first quarter of 2025 were $896 thousand, up 39% compared to $647 thousand in the first quarter of 2024. Unit sales increased approximately 46% year over year due to growth from patients with full insurance reimbursement and the Company's financial assistance program that offers discounts for patients without insurance coverage. The Company continues to see great improvements in recent months, gaining positive policy coverage for the PENFS technology, and recent results are indicative of that success. Gross margin in the first quarter of 2025 declined to 84.4% from 88.4% in the first quarter of 2024. Despite the increase in sales volume, the decline in gross margin is the result of higher growth from financial assistance customers with discounted pricing due to lack of insurance coverage compared to full reimbursement customers with insurance coverage and higher device manufacturing and shipping costs. Operating expenses in the first quarter of 2025 were $3.1 million, an increase of 27% compared to $2.4 million in the first quarter of 2024. The increase is due to (i) the settlement of a lawsuit, (ii) higher selling expenses corresponding directly with sales volume and (iii) higher research and development costs as the Company completed RED development and initiated expenditures on a new medical research project. Excluding the one-time legal settlement charge, the Company's operating expenses in the first quarter of 2025 would have remained relatively flat compared to the first quarter of 2024. Operating loss in the first quarter of 2025 was $2.3 million, an increase of 25% compared to $1.8 million in the first quarter of 2024. Excluding the one-time legal settlement charge, the Company's operating loss in the first quarter of 2025 would have improved 9% compared to the first quarter of 2024. Net loss in the first quarter of 2025 was $2.3 million, an increase of 8% compared to $2.1 million in the first quarter of 2024. Excluding the one-time legal settlement charge, the Company's net loss in the first quarter of 2025 would have improved 22% compared to the first quarter of 2024. Cash on hand as of March 31, 2025, was $2.0 million. Cash used in operations in the first quarter of 2025 was $271 thousand higher than in the first quarter of 2024 primarily due to past due payables in the first quarter of 2024 that was a function of the Company's liquidity position at the time. The Company has no long-term debt. Conference Call Details Date and Time: Monday, May 12, 2025, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at or For participants listening through the webcast, questions can be sent in through the portal using the 'Ask a Question' link or by emailing questions to NRXS@ Call-in Information: Interested parties can also access the live conference call by initially registering at the following link. Upon completion of the registration link, call-in participants will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details. Replay: A webcast replay will be available in the Investor Relations section of the Company's website at orhttps:// About NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit Forward-Looking StatementsCertain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company's stock, public health issues or other events, the Company's compliance with applicable laws, the results of the Company's clinical trials and perceptions thereof, the results of submissions to the FDA, the results of the shareholder vote to enable the issuance of the Preferred Stock, and factors described in the Risk Factors section of NeurAxis's public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. For contraindications, precaution, warnings, and IFU, please see: For important RED information, including indications, precautions, and contraindications, visit: Contacts: CompanyNeurAxis, Investor Relations Lytham PartnersBen Shamsian646-829-9701shamsian@ (Unaudited) For the Three Months EndedMarch 31, 2025 2024 Net Sales $ 895,655 $ 646,635 Cost of Goods Sold 139,475 75,081 Gross Profit 756,180 571,554 Selling Expenses 133,954 80,030 Research and Development 60,556 5,570 General and Administrative 2,856,768 2,318,074 Operating Loss (2,295,098 ) (1,832,120 ) Other income (expense): Financing charges — (230,824 ) Interest expense (2,237 ) (26,560 ) Change in fair value of warrant liability 1,831 (9,284 ) Amortization of debt discount and issuance cost — (21,683 ) Other income 16,820 — Other expense — (180 ) Total other income (expense), net 16,414 (288,531 ) Net loss (2,278,684 ) (2,120,651 ) Preferred stock dividends (213,543 ) — Net loss available to common stockholders $ (2,492,227 ) $ (2,120,651 ) Per-Share Data Basic and diluted loss per share $ (0.33 ) $ (0.32 ) Weighted Average Common Shares Outstanding Basic and diluted 7,463,578 6,550,567
Yahoo
09-05-2025
- Climate
- Yahoo
Keller Williams employees volunteer at McCook Lake
NORTH SIOUX CITY, S.D. (KCAU) — Flooding is not a concern in Siouxland like it was last year, but residents at McCook Lake are continuing to pick up the pieces. Property owners near the lake got some extra clean up help Thursday from volunteers with Keller Williams. This is the ninth year the company has held 'RED (Renew, Energize, Donate) Day' where each location closes to help out in their local community. Ashley Johnson, the agent services coordinator at Keller Williams Siouxland, told KCAU 9 exactly their team was doing to help. Story continues below Top Story: Catholic Diocese of Sioux City comments on first American Pope Crime: Sioux City man sentenced for stealing keys, taking off in car Sports: South Dakota softball advances to Summit League semifinals 'We got some people out on the island picking up maybe some debris that's washed out there,' Johnson said. 'We got some working back at Izaak Walton, specifically helping get stuff ready for the season there, and then we're out here helping some the homeowners clean up the shorelines as well.' Johnson added that with so much debris still buried under the sand and mud, she thinks it could could take years to get the lake back to where it once was. The Izaak Walton League continues to assist in clear up at McCook Lake as well. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
